title: Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer.
abstract: Triple-negative breast cancer is difficult to treat because of the lack of rationale-based therapies. There are no established markers and targets that can be used for stratification of patients and targeted therapy. Here we report the identification of novel molecular features, which appear to augment metastasis of triple negative breast tumors. We found that triple-negative breast tumors can be segregated into 2 phenotypes based on their genome-wide protein abundance profiles. The first is characterized by high expression of Stat1, Mx1, and CD74. Seven out of 9 tumors from this group had invaded at least 2 lymph nodes while only 1 out of 10 tumors in group 2 was lymph node positive. In vitro experiments showed that the interferon-induced increase in Stat1 abundance correlates with increased migration and invasion in cultured cells. When CD74 was overexpressed, it increased cell adhesion on matrigel. This effect was accompanied with a marked increase in the membrane expression of beta-catenin, MUC18, plexins, integrins, and other proteins involved in cell adhesion and cancer metastasis. Taken together, our results show that Stat1/CD74 positive triple-negative tumors are more aggressive and suggest an approach for development of better diagnostics and more targeted therapies for triple negative breast cancer. This article is part of a Special Issue entitled: Proteomics: The clinical link.
authors.affiliation: The Helen Rollason Research Laboratory, Anglia Ruskin University, Chelmsford, Essex, CM1 1SQ, United Kingdom.
authors.forename: Christina
authors.initials: C
authors.lastname: Greenwood
authors.forename: Gergana
authors.initials: G
authors.lastname: Metodieva
authors.forename: Khalid
authors.initials: K
authors.lastname: Al-Janabi
authors.forename: Berthold
authors.initials: B
authors.lastname: Lausen
authors.forename: Louise
authors.initials: L
authors.lastname: Alldridge
authors.forename: Lin
authors.initials: L
authors.lastname: Leng
authors.forename: Richard
authors.initials: R
authors.lastname: Bucala
authors.forename: Nelson
authors.initials: N
authors.lastname: Fernandez
authors.forename: Metodi V
authors.initials: MV
authors.lastname: Metodiev
mesh_terms: D000944:Antigens, Differentiation, B-Lymphocyte / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism; D001943:Breast Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology*; D002277:Carcinoma / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology*; D045744:Cell Line, Tumor; D002853:Chromatography, Liquid; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000378:metabolism*; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D009361:Neoplasm Invasiveness; D011379:Prognosis; D050794:STAT1 Transcription Factor / Q000378:metabolism*; D053719:Tandem Mass Spectrometry; D015854:Up-Regulation
chemical_list: D000944:Antigens, Differentiation, B-Lymphocyte; D014408:Biomarkers, Tumor; D000949:Histocompatibility Antigens Class II; D050794:STAT1 Transcription Factor; C494079:STAT1 protein, human; C045084:invariant chain